Patient engagement in Life Sciences is changing quickly. Search, AI, telehealth and direct-to-patient models are reshaping where healthcare journeys begin and how people make decisions along the way. BioPharma has responded with new digital channels and patient platforms, but the experience remains fragmented. More portals have not necessarily created a simpler or more connected patient journey.
Beyond the Portal looks at what this shift means for BioPharma. It examines where meaningful gaps still exist across discovery, diagnosis, treatment initiation and ongoing management, and where companies can realistically play a larger role. It also draws an important distinction between areas BioPharma can own and those where partnership, enablement or funding may be the better route.
The paper presents a practical framework for deciding where to focus. Rather than approaching patient engagement brand by brand, it proposes looking at the journey through patient archetypes, identifying where friction and opportunity are greatest, assessing value across five dimensions, and then deciding whether to build, partner or fund. The aim is not to create another portal, but to establish a more relevant and connected role in the patient journey.